Table 2.
ALDH | HIF1A | HIF2A | ||||||
Parameter | Positive(n = 25) | Negative(n = 50) | p* | Positive(n = 38) | Negative(n = 37) | p* | QS (median) | p** |
Age (mean ± SD) | 45±10 | 51±11 | 0.02 | 47±11 | 51±11 | 0.1 | r = −0.11 | 0.3 |
Menopausal status (n) | ||||||||
Pre | 18 | 26 | 24 | 19 | 100 | |||
Post | 7 | 24 | 0.09 | 14 | 18 | 0.3 | 55 | 0.1 |
Clinical stage (n) | ||||||||
II | 14 | 23 | 17 | 20 | 80 | |||
III | 11 | 27 | 0.4 | 21 | 17 | 0.5 | 80 | 0.9 |
Grade (n) | ||||||||
1/2 | 17 | 40 | 25 | 33 | 65 | |||
3 | 8 | 10 | 0.2 | 13 | 4 | 0.02 | 100 | 0.2 |
ER positive (n) | 16 | 32 | 1.0 | 21 | 28 | 0.08 | 80 | 0.8 |
PgR positive (n) | 11 | 23 | 1.0 | 15 | 20 | 0.2 | 75 | 0.9 |
HER2 positive (n) | 7 | 13 | 1.0 | 12 | 8 | 0.4 | 60 | 0.4 |
Clinical response (n) | ||||||||
OR | 20 | 41 | 33 | 28 | 80 | |||
NR | 5 | 9 | 1.0 | 5 | 9 | 0.2 | 70 | 0.8 |
pCR (n) | 4 | 6 | 0.7 | 8 | 2 | 0.03 | 90 | 0.6 |
ALN (n) | ||||||||
Positive | 12 | 31 | 18 | 25 | 65 | |||
Negative | 12 | 19 | 0.4 | 19 | 12 | 0.09 | 100 | 0.08 |
ER, estrogen receptor; OR, objective response; NR, no response; pCR, complete pathological response; ALN, axillary lymph node; * Fisher's exact test; **median test.